- Adults (18-64 years)
- Hospital
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Blood sample
- Nasopharyngeal swab
- PBMC
- Serum
- Stool sample
- Whole blood
- Plasma
Setting: Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Community
- Primary care
- Emergency department
- Non-hospital health centre
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Community
- Non-hospital health centre
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Non-hospital health centre
- Long-term care facility
- Influenza virus
- Influenza A(H5N1) virus
- Influenza A(H7N9) virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Immunocompromised host
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab